A Phase 2 interventional study of [123I]ß CIT and SPECT imaging in Parkinsonian Syndrome, sponsored by Institute for Neurodegenerative Disorders. Completed at 1 site in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-02.
Sponsored by Institute for Neurodegenerative Disorders · Phase 2, Interventional, and Diagnostic
This study involves study participants who have been clinically diagnosed with parkinsonian syndrome or who are at-risk for parkinsonian syndrome, have a family history of parkinsonian syndrome or exposure to environmental toxins potentially associated with parkinsonian syndrome. Participants will have brain imaging to assess dopamine transporter density. The imaging data coupled with family history and environmental exposure data may provide important information about potential risk factors for parkinsonian syndrome.
The brain imaging is conducted at the Institute for Neurodegenerative Disorders in New Haven, Connecticut. The imaging procedure occurs over a two day period.
On the first day participants are injected with [123I]ß CIT, an investigational radioactive material that localizes in the brain. Study participants will also have a thorough neurologic examination and standard neuropsychological testing, including testing of memory, concentration, abstraction and visual spatial functions.
Twenty-four hours later study participants return to the Institute for Neurodegenerative Disorders where an investigational scanning procedure will be used to obtain SPECT (single photon emission computed tomography) images of the brain.
Participants may be contacted to repeat these procedures every 12 to 18 months.
235 studies on the registry are indexed under Parkinsonian Disorders; 69 are open to participants now.
This study's enrollment of 232 is above the median of 55 across 143 interventional studies indexed under Parkinsonian Disorders.
Browse Parkinsonian Disorders studies →Institute for Neurodegenerative Disorders is the lead sponsor of 40 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
To assess \[123I\]ß-CIT and SPECT imaging
Drug: [123I]ß CIT and SPECT imaging
To assess \[123I\]ß CIT and SPECT imaging
Also known as: [123I]ß CIT, SPECT imaging
CIT uptake is the Specific: Nondisplaceable striatal uptake ratio
Time frame: 2 yrs
CIT uptake measures from at-risk individuals will be compared with healthy subjects.
Time frame: 2 yrs
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute for Neurodegenerative Disorders